{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T11:14:54Z","timestamp":1700565294499},"reference-count":53,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,2]],"date-time":"2012-01-02T00:00:00Z","timestamp":1325462400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie in unserer Zeit"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Viele H\u00fcrden erschweren die Forschung nach neuen Antituberkulotika. Nicht nur neue Substanzen werden dringend ben\u00f6tigt, auch die Kriterien zur Bewertung, neue Tiermodelle und Biomarker sind unumg\u00e4nglich. Die schon vielversprechende Pipeline ist ein Ergebnis vieler Initiativen in der TB\u2010Forschung, vor allem die Arbeit der Private\u2010Public\u2010Partnerships leistet einen gro\u00dfen Beitrag, neue Substanzen in die Pipeline zu \u201cbef\u00f6rdern\u201d. Zum Gl\u00fcck scheint auch die Industrie \u201cerwacht\u201d, an Tuberkulose zu forschen, wie ein sprunghafter Anstieg der Firmenpatente mit dem Thema Tuberkulose in den letzten acht Jahren zeigt. Der aussichtsreichste Wirkstoff in der Pipeline ist derzeit TMC207 (Bedaquilin).<\/jats:p>","DOI":"10.1002\/pauz.201100452","type":"journal-article","created":{"date-parts":[[2012,1,2]],"date-time":"2012-01-02T11:51:25Z","timestamp":1325505085000},"page":"48-57","source":"Crossref","is-referenced-by-count":0,"title":["Die Suche nach neuen Antituberkulotika"],"prefix":"10.1002","volume":"41","author":[{"given":"Katja","family":"Laqua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Imming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,2]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/11538170-000000000-00000"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09657"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12038-008-0078-8"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2009.08.011"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09247"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1816"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2004.08.011"},{"key":"e_1_2_1_9_2","first-page":"11","article-title":"Animal models of tuberculosis for vaccine development.","volume":"129","author":"Gupta U.D.","year":"2009","journal-title":"Indian J. Med. Res."},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1065"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939542"},{"key":"e_1_2_1_12_2","first-page":"1075","article-title":"Tuberculosis in humans and animals: an overview.","volume":"14","author":"LoBue P.A.","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","unstructured":"Cave M.D. Murray M. Nardell E.A.: Molecular Epidemiology of Mycobacterium tuberculosis. In: Cole S.T. Eisenach K.D. McMurray D.N. (eds.): Tuberculosis and the Tubercle Bacillus. Washington DC (2005) pp. 33\u201346.","DOI":"10.1128\/9781555817657.ch3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2201"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.10.50"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171583"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.08.001"},{"key":"e_1_2_1_18_2","unstructured":"EMA. Public summary of opinion on orphan designation. Rifapentine for the treatment of tuberculosis. London (2010)."},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1106753"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01775.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2010.04.008"},{"key":"e_1_2_1_22_2","unstructured":"Arora S.K. Sinha N. Sinha R. Bateja R. Sharma S. Upadhayaya R.S.: Design synthesis modelling and activity of novel anti tubercular compounds. Abstracts of Papers 227th ACS National Meeting Anaheim CA United States March 28\u2013April 1. (2004)."},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1472-9792(08)70015-5"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki319"},{"key":"e_1_2_1_25_2","unstructured":"Sequella Antibiotic Pipeline. http:\/\/www.sequella.com\/pipeline\/index.html. Accessed 11.07.2011."},{"key":"e_1_2_1_26_2","unstructured":"Clinical Trial Reference Number NCT00425113. www.clinicaltrials.gov. Accessed 23.05.2011."},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.5.1285"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164571"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1039\/b915877d"},{"key":"e_1_2_1_30_2","unstructured":"Clinical Trial Reference Number NCT00727844 NCT00664313 NCT00691392. www.clinicaltrials.gov. Accessed 23.05.2011."},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01182-08"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm950956y"},{"key":"e_1_2_1_33_2","unstructured":"Clinical Trial Reference Number NCT01225640. www.clinicaltrials.gov. Accessed 23.05.2011."},{"key":"e_1_2_1_34_2","unstructured":"Clinical Trial Reference Number NCT01116258. www.clinicaltrials.gov. Accessed 28.07.2011."},{"key":"e_1_2_1_35_2","unstructured":"TB Alliance Portfolio. www.tballiance.org. Accessed 17.06.2011."},{"key":"e_1_2_1_36_2","unstructured":"Stop TB Partnership Pipeline. www.newtbdrugs.org. Accessed 17.06.2011."},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01514-10"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00853-07"},{"key":"e_1_2_1_39_2","unstructured":"Ma Z.: Vortrag: Global TB Drug Pipeline: The Need and the Reality. Workshop on Advanced Design an Development of Potential Drugs against Tuberculosis. Die Wilgers South Africa (2009)."},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1021\/jo702264e"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(03)00596-1"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00366-09"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.10.135"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja106357w"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-09"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm1012006"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2008.02.003"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi9016186"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08357"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2010.06.009"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2009.01.002"},{"key":"e_1_2_1_52_2","unstructured":"BioInfoBank Library: MM4TB. http:\/\/lib.bioinfo.pl\/projects\/view\/26926. Accessed 12.08.2011."},{"key":"e_1_2_1_53_2","unstructured":"Koch O. Doil N. Heller K. Stuhlmann F. Schmitt S. et al.: Vortrag: A new player in the fight against tuberculosis: Thioredoxin Reductase inhibitors with high bioactivity on M. tuberculosis. Frontiers in Medicinal Chemistry. Saarbruecken (2011)."},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909133107"}],"container-title":["Pharmazie in unserer Zeit"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpauz.201100452","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpauz.201100452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pauz.201100452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T10:51:25Z","timestamp":1700563885000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pauz.201100452"}},"subtitle":["Bessere Suchstrategien, hoffnungsvolle Kandidaten"],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["10.1002\/pauz.201100452"],"URL":"https:\/\/doi.org\/10.1002\/pauz.201100452","archive":["Portico"],"relation":{},"ISSN":["0048-3664","1615-1003"],"issn-type":[{"value":"0048-3664","type":"print"},{"value":"1615-1003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}